LEGN vs. VKTX, ASND, CERE, ROIV, JAZZ, ITCI, CYTK, ELAN, BPMC, and CTLT
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Viking Therapeutics (VKTX), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Roivant Sciences (ROIV), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
Viking Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.
In the previous week, Legend Biotech had 8 more articles in the media than Viking Therapeutics. MarketBeat recorded 29 mentions for Legend Biotech and 21 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.54 beat Legend Biotech's score of 0.50 indicating that Legend Biotech is being referred to more favorably in the news media.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -135.92%. Legend Biotech's return on equity of -18.41% beat Viking Therapeutics' return on equity.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Viking Therapeutics has higher earnings, but lower revenue than Legend Biotech. Viking Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics presently has a consensus target price of $112.38, suggesting a potential upside of 67.72%. Legend Biotech has a consensus target price of $82.74, suggesting a potential upside of 83.21%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Legend Biotech is more favorable than Viking Therapeutics.
Viking Therapeutics received 540 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 64.13% of users gave Legend Biotech an outperform vote.
Summary
Viking Therapeutics beats Legend Biotech on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
